Literature DB >> 3669780

Specificity of fibrinopeptide A (FpA) as a marker for gastrointestinal cancers before and after surgery.

V Abbasciano1, F Levato, G Zavagli.   

Abstract

In 70 patients affected by gastrointestinal malignancies the plasma fibrinopeptide A (FpA) levels were assessed both before and at various intervals after the operation. At the same time other more commonly used tests of coagulation were carried out. In all the patients plasma FpA levels were shown to be variously elevated, so that they could give useful clues to the diagnosis, treatment, prognosis and follow-up of the gastrointestinal malignancies. In all the patients the coagulation tests fell into the normal ranges. However in the patients affected by recto-sigmoid adenocarcinoma an increase of circulating fibrin degradation products (FDPs) was observed which paralleled the increase of plasma FpA. In conclusion, in gastrointestinal malignancies the increase of plasma FpA levels suggests the cancer-induced start of the coagulation cascade. The assay of this peptide proves to be a reliable marker for these diseases.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3669780     DOI: 10.1007/bf02934943

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  12 in total

1.  A radioimmunoassay technique for the rapid measurement of human fibrinopeptide A.

Authors:  V Hofmann; P W Straub
Journal:  Thromb Res       Date:  1977-08       Impact factor: 3.944

2.  Fibrinopeptide A in plasma of normal subjects and patients with disseminated intravascular coagulation and systemic lupus erythematosus.

Authors:  M Cronlund; J Hardin; J Burton; L Lee; E Haber; K J Bloch
Journal:  J Clin Invest       Date:  1976-07       Impact factor: 14.808

3.  The activation of coagulation by extracts of mucus: a possible pathway of intravascular coagulation accompanying adenocarcinomas.

Authors:  G F Pineo; E Regoeczi; M W Hatton; M C Brain
Journal:  J Lab Clin Med       Date:  1973-08

4.  Diagnostic value of fibrinopeptide A and beta-thromboglobulin in acute deep venous thrombosis and pulmonary embolism.

Authors:  H van Hulsteijn; E Briët; C Koch; J Hermans; R Bertina
Journal:  Acta Med Scand       Date:  1982

5.  Activation of blood coagulation in cancer: Trousseau's syndrome revisited.

Authors:  F R Rickles; R L Edwards
Journal:  Blood       Date:  1983-07       Impact factor: 22.113

6.  Significance of plasma fibrinopeptide A and high molecular weight fibrinogen in patients with liver cirrhosis.

Authors:  S Coccheri; P M Mannucci; G Palareti; W Gervasoni; M Poggi; S Viganò
Journal:  Br J Haematol       Date:  1982-11       Impact factor: 6.998

7.  Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease.

Authors:  G J Gasic; T B Gasic; N Galanti; T Johnson; S Murphy
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

8.  Plasma fibrinopeptide A and beta-thromboglobulin in major bacterial infections.

Authors:  H van Hulsteijn; W Fibbe; R Bertina; E Briët
Journal:  Thromb Haemost       Date:  1982-12-27       Impact factor: 5.249

9.  Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation.

Authors:  R L Edwards; F R Rickles; M Cronlund
Journal:  J Lab Clin Med       Date:  1981-12

10.  A factor X-activating cysteine protease from malignant tissue.

Authors:  S G Gordon; B A Cross
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

View more
  2 in total

1.  Differential exoprotease activities confer tumor-specific serum peptidome patterns.

Authors:  Josep Villanueva; David R Shaffer; John Philip; Carlos A Chaparro; Hediye Erdjument-Bromage; Adam B Olshen; Martin Fleisher; Hans Lilja; Edi Brogi; Jeff Boyd; Marta Sanchez-Carbayo; Eric C Holland; Carlos Cordon-Cardo; Howard I Scher; Paul Tempst
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

2.  Specificity of tumor markers (CEA, GICA, TPA, alpha-FP, FpA, gamma-GT) for the diagnosis of hepatic metastases from large bowel cancers.

Authors:  V Abbasciano; F Levato; G Zavagli
Journal:  Med Oncol Tumor Pharmacother       Date:  1989
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.